分析男性睾丸激素抑制接收histrelin,小说促性腺激素治疗前列腺癌。

文章的细节

引用

复制到剪贴板

Djavan B, Schlegel P,所罗门G, Eckersberger E,距首都普里什蒂纳H, Graefen M

分析男性睾丸激素抑制接收histrelin,小说促性腺激素治疗前列腺癌。

可以8月杂志。2010;17 (4):5265 - 71。

PubMed ID

20735905 (在PubMed

]

文摘

背景:雄激素剥夺疗法(ADT)是男性晚期前列腺癌的标准治疗。连续睾丸激素抑制治疗效果至关重要。最近1年得宝化合物,histrelin (VANTAS:猎户座制药、芬兰;Endo制药,美国),促性腺激素释放激素(GnRH)模拟,通过激素治疗的前列腺癌。在目前的调查研究这种化合物的治疗效果,除了影响睾酮值和速度以及PSA。方法:一百三十一例前列腺癌组织学证实和睾酮水平正常的前瞻性评估超过1年。雄激素剥夺疗法使用一次执行年度植入的促性腺histrelin。血清睾酮和PSA水平和histrelin剖面测量前瞻性每月1年。此外,患者根据其PSA结果分层和D中保风险。结果:睾丸激素抑制睾酮(< = 50毫微克/分升)测定在周4和52之间所有的病人; 88% of patients had a continuous testosterone level under 20 ng/dL. The PSA level in the total population decreased significantly within the first 2 weeks compared with baseline, and after 52 weeks the median PSA level of the total population was 0.2 ng/mL. PSA responses were grouped into three typical therapeutic outcomes and correlated with the clinical risk distribution, and levels were lowered in all three risk groups. CONCLUSION: The GnRH agonist histrelin successfully suppressed testosterone over the entire study period. This effect was measured across a number of different clinical definitions of PSA response and clinical risk. The GnRH agonist therefore offers an effective therapy option in hormone treatment of prostate cancer.

DrugBank数据引用了这篇文章

药物

Histrelin